We aimed to provide an updated narrative review with respect to the RET pathogenic variants and their implications at the clinical (dermatology and endocrinology assessments) and molecular level in the diagnosis of MTC/multiple endocrine neoplasia (MEN) type 2, particularly with respect to the presence of cutaneous lichen amyloidosis (CLA). This evidence concerns the gene RET and medullary thyroid gland carcinoma.